PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea flag South Korea · Delayed Price · Currency is KRW
644,000
-9,000 (-1.38%)
Sep 12, 2025, 3:30 PM KST

PharmaResearch Statistics

Total Valuation

PharmaResearch has a market cap or net worth of KRW 6.69 trillion. The enterprise value is 6.45 trillion.

Market Cap6.69T
Enterprise Value 6.45T

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date Nov 13, 2025
Ex-Dividend Date Dec 27, 2024

Share Statistics

PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 2.29% in one year.

Current Share Class 10.39M
Shares Outstanding 10.39M
Shares Change (YoY) +2.29%
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.53%
Owned by Institutions (%) 14.87%
Float 9.15M

Valuation Ratios

The trailing PE ratio is 52.61 and the forward PE ratio is 31.89. PharmaResearch's PEG ratio is 0.65.

PE Ratio 52.61
Forward PE 31.89
PS Ratio 14.88
PB Ratio 10.49
P/TBV Ratio 11.57
P/FCF Ratio 59.10
P/OCF Ratio 45.28
PEG Ratio 0.65
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.98, with an EV/FCF ratio of 56.94.

EV / Earnings 50.76
EV / Sales 14.33
EV / EBITDA 34.98
EV / EBIT 38.09
EV / FCF 56.94

Financial Position

The company has a current ratio of 7.76, with a Debt / Equity ratio of 0.33.

Current Ratio 7.76
Quick Ratio 6.75
Debt / Equity 0.33
Debt / EBITDA 1.14
Debt / FCF 1.85
Interest Coverage 17.73

Financial Efficiency

Return on equity (ROE) is 20.92% and return on invested capital (ROIC) is 15.20%.

Return on Equity (ROE) 20.92%
Return on Assets (ROA) 13.87%
Return on Invested Capital (ROIC) 15.20%
Return on Capital Employed (ROCE) 20.05%
Revenue Per Employee 999.58M
Profits Per Employee 282.21M
Employee Count 450
Asset Turnover 0.59
Inventory Turnover 2.05

Taxes

In the past 12 months, PharmaResearch has paid 36.38 billion in taxes.

Income Tax 36.38B
Effective Tax Rate 23.27%

Stock Price Statistics

The stock price has increased by +248.86% in the last 52 weeks. The beta is 0.60, so PharmaResearch's price volatility has been lower than the market average.

Beta (5Y) 0.60
52-Week Price Change +248.86%
50-Day Moving Average 616,750.00
200-Day Moving Average 402,102.00
Relative Strength Index (RSI) 49.90
Average Volume (20 Days) 84,876

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, PharmaResearch had revenue of KRW 449.81 billion and earned 126.99 billion in profits. Earnings per share was 12,241.81.

Revenue449.81B
Gross Profit 332.86B
Operating Income 169.23B
Pretax Income 156.37B
Net Income 126.99B
EBITDA 184.30B
EBIT 169.23B
Earnings Per Share (EPS) 12,241.81
Full Income Statement

Balance Sheet

The company has 481.06 billion in cash and 209.62 billion in debt, giving a net cash position of 271.44 billion or 26,126.11 per share.

Cash & Cash Equivalents 481.06B
Total Debt 209.62B
Net Cash 271.44B
Net Cash Per Share 26,126.11
Equity (Book Value) 638.13B
Book Value Per Share 58,862.69
Working Capital 533.91B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 147.77 billion and capital expenditures -34.55 billion, giving a free cash flow of 113.22 billion.

Operating Cash Flow 147.77B
Capital Expenditures -34.55B
Free Cash Flow 113.22B
FCF Per Share 10,897.08
Full Cash Flow Statement

Margins

Gross margin is 74.00%, with operating and profit margins of 37.62% and 28.23%.

Gross Margin 74.00%
Operating Margin 37.62%
Pretax Margin 34.76%
Profit Margin 28.23%
EBITDA Margin 40.97%
EBIT Margin 37.62%
FCF Margin 25.17%

Dividends & Yields

This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.17%.

Dividend Per Share 1,100.00
Dividend Yield 0.17%
Dividend Growth (YoY) 15.79%
Years of Dividend Growth 5
Payout Ratio 9.46%
Buyback Yield -2.29%
Shareholder Yield -2.12%
Earnings Yield 1.90%
FCF Yield 1.69%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

PharmaResearch has an Altman Z-Score of 8.34 and a Piotroski F-Score of 7.

Altman Z-Score 8.34
Piotroski F-Score 7